OSLO (Reuters) – Novo Nordisk will on Tuesday begin the execution of its planned share buyback programme for 2024, the Danish maker of obesity drug Wegovy and diabetes treatment Ozempic said in a statement.
Novo on Jan. 31 said it planned to carry out a share repurchase plan of up to 20 billion Danish crowns ($2.88 billion) to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes.
The company completed its previous 12-month share repurchase programme on Jan. 30.
($1 = 6.9337 Danish crowns)
(Reporting by Terje Solsvik, editing by Anna Ringstrom and Essi Lehto)
Comments